Low molecular weight heparin versus aspirin for acute ischemic stroke: A systematic review

Journal of Stroke and Cerebrovascular Diseases

Volumn 11, Issue 2, 2002, Pages 55-62

  Bath, Philip ^a   Leonardi Bee, Jo ^a   Bath, Fiona ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Acute ischemic stroke; Aspirin; Deep vein thrombosis; Low molecular weight heparin; Symptomatic intracranial hemorrhage

Indexed keywords

ACETYLSALICYLIC ACID; CERTOPARIN; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN;

BLEEDING; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FATALITY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; STROKE; SYMPTOMATOLOGY; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0036522443     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1053/jscd.2002.126694     Document Type: Article

References (27)

1. International Stroke Trial Collaborative Group. The International Stroke Trial (IST); A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
2. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641-1649.
3. Gubitz G, Counsell C, Sandercock P, et al. Anticoagulants for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library (Ed 4) Oxford: Update Software, et al. 2001.
4. Chen Z-M, Sandercock P, Pan H-C, et al. Indications for early aspirin use in acute ischemic stroke. Stroke 2000;31:1240-1249.
5. Leizorovicz A, Haugh MC, Chapuis F-R, et al. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992;305:913-920.
6. Lensing WA, Prins MH, Davidson BL, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta analysis. Arch Intern Med 1995;155:601-607.
7. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
8. Bath PMW. Low molecular weight heparin in acute stroke. Expert Opin Investig Drugs 1998;7:1323-1330.
9. Bath PMW, Iddenden R, Bath FJ. Low molecular weight heparins and heparinoids in acute ischaemic stroke: A systematic review. Stroke 2000;31:311-314.
10. Sandercock PAG, van den Belt AGM, Lindley RI, et al. Antithrombotic therapy in acute ischaemic stroke: An overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993;56:17-25.
11. Counsell C, Sandercock P. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library Ed 4. Oxford: Update Software, 2001.
12. Samama MM, Desnoyers PC, Bousser MG. Acute ischemic stroke and heparin treatments. Thromb Haemost 1997;78:173-179.
13. Hankey GJ. Heparin in acute ischaemic stroke. The T wave is negative and it's time to stop. Med J Aust 1998;169:534-536.
14. Lensing AWA. Anticoagulation in acute ischemic stroke: Deep vein thrombosis prevention and long-term stroke outcomes. Blood Coagul Fibrinolysis 1999;10:S123-S127.
15. Chamorro A. Heparin in acute ischemic stroke: The case for a new clinical trial. Cerebrovasc Dis 1999;9:16-23 (suppl 3).
16. Bath FJ, Owen VE, Bath PMW. Quality of full and final publications reporting acute stroke trials. A systematic review. Stroke 1998;29:2203-2210.
17. Bath P, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): A randomised aspirin-controlled trial. Lancet 2001;358:702-710.
18. Berge E, Sandset PM. Heparin in acute embolic stroke trial (HAEST). In: Cerebrovascular Diseases 1999;9:127. (abstr) (suppl 1)
19. Berge E, Abdelnoor M, Nakstad PH, et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: A double-blind randomised study. Lancet 2000;355:1205-1210.
20. Diener HC, Ringlestein EB, von Kummer R, et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin. Results of the TOPAS trial. Stroke 2001;32:22-29.
21. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
22. Li P, He Q, Siddiqui MM, et al. Posttreatment with low molecular weight heparin reduces brain edema and infarct volume in rats subjected to thrombotic middle cerebral artry occlusion. Brain Res 1998;801:220-223.
23. Quartermain D, Yong-sheng L, Jonas S. Enoxaparin, a low molecular weight heparin decreases infarct size and improves sensorimotor function in a rat model of focal cerebral ischemia. Neurosci Lett 2000;288:155-158.
24. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke. JAMA 1998;279:1265-1272.
25. Hommel M, Group fTFbI. Fraxiparine in ischaemic stroke study (FISS bis). In: Cerebrovascular Diseases 1998;8:9. (abstr)
26. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI IIB-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
27. Leonardi-Bee J, Bath F, Bath P. Comparison of low molecular weight heparin with aspirin in the treatment of acute ischaemic stroke: A systematic review. Cerebrovasc Dis 2001;11:75. (abstr) (suppl 4)